The negative correlation between PD1 signaling and the prognostic factors indicates that targeting the PD1 immune checkpoint during cancer immunotherapy may contribute to atherosclerosis development and ischemic risk through the macrophage related ceRNA subnetwork. This evidence concerns the gene PDCD1 and atherosclerosis.